Clinical Trials Browser

Recurrence × quizartinib × 90 days × Clear all

NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute